Cancer Innovation - Wiley Online Library
Cancer Innovation is a high-quality, open access oncology journal publishing innovative papers on all aspects of basic and clinical cancer research.
Cancer Innovation - Wiley Online Library

- Skip to Main Content

[![Wiley Online Library](/pb-assets/hub-assets/pericles/logo-header-1690978619437.png)](/ "")

[![Wiley Online Library](/pb-assets/hub-assets/pericles/mobilehublogo-1690978876347.png)](/ "")

Search withinThis JournalAnywhere

- Search term

[Advanced Search](https://onlinelibrary.wiley.com/search/advanced?publication=27709183 "") [Citation Search](https://onlinelibrary.wiley.com/search/advanced?publication=27709183#citation "")

- Search term

[Advanced Search](https://onlinelibrary.wiley.com/search/advanced "") [Citation Search](https://onlinelibrary.wiley.com/search/advanced#citation "")


Login / Register

- [Individual login](/action/showLogin?acdl-redirect=true&uri=%2Fjournal%2F27709183)
- [Institutional login](/action/ssostart?redirectUri=%2Fjournal%2F27709183)
- [REGISTER](/action/registration?redirectUri=%2Fjournal%2F27709183&acdl-redirect=true)

[**Cancer Innovation**![Cancer Innovation](/pb-assets/journal-banners/27709183-1649314915053.jpg)](/journal/27709183 "Cancer Innovation homepage")

Editor-in-Chief: Fei Ma

[JOURNAL METRICS >](/journal/27709183/journal-metrics)

Online ISSN:2770-9183

Print ISSN:2770-9191

Tsinghua University Press

- [![Cancer Innovation](/cms/asset/6b6b75da-29c3-4cb7-a0a3-c17a0026dbd2/cai2.v3.5.cover.gif)](/toc/27709183/2024/3/5 "Cancer Innovation")

[LATEST ISSUE  >](/toc/27709183/2024/3/5 "Go to latest issue")

Volume 3, Issue 5



October 2024


[menu drawer](#undefined "menu drawer")

## Navigation Bar

### Menu

[Home](/)

- [Home](/journal/27709183)
- About
  - [Overview](/page/journal/27709183/homepage/productinformation.html)
  - [Journal Metrics](/journal/27709183/journal-metrics)
  - [Society Information](/page/journal/27709183/homepage/society)
  - [Contact](/page/journal/27709183/homepage/contact)
  - [Editorial Board](/page/journal/27709183/homepage/editorial-board)
  - [OA Advantages](/page/journal/27709183/homepage/oa-advantages)
  - [Advertise](/page/journal/27709183/homepage/advertise)
  - [Permissions](/page/journal/27709183/homepage/permissions)
- Contribute
  - [Author Guidelines](/page/journal/27709183/homepage/author-guidelines)
  - [Open Access](/page/journal/27709183/homepage/open-access)
  - [Submit a Manuscript](https://mc.manuscriptcentral.com/cancerinnovation)
  - [For Referees](/page/journal/27709183/homepage/referees)
- Browse
  - [Accepted Articles](/toc/27709183/0/ja)
  - [Early View](/toc/27709183/0/0)
  - [Current Issue](/toc/27709183/current)
  - [All Issues](/loi/27709183)
  - [Special Issues](/page/journal/27709183/homepage/special-issues)
- [Themed Collections](/topic/vi-categories-27709183/themed-collections/27709183)

## Follow journal

- [Alert](/action/doUpdateAlertSettings?action=addJournal&journalCode=27709183)
- [Facebook page](https://www.facebook.com/WileyOncologyNews "Facebook page")
- [Twitter channel](https://twitter.com/WileyOnc_Hem "Twitter channel")
- RSS Feeds

- [Most recent (RSS)](/feed/27709183/most-recent)
- [Most cited (RSS)](/feed/27709183/most-cited)

_Cancer Innovation_ is a high-quality, open access journal covering key topics in all aspects of cancer research, focusing on emerging interdisciplinary, strategic frontiers and key common technologies in oncology.

**A new frontier in innovative oncology solutions**. _Cancer Innovation_ provides timely updates on advances and unmet needs, bringing innovative oncology solutions to life.

**Presenting a unique combination of oncology research, innovation, and data.** _Cancer Innovation_ bridges the gap between biological, medical, engineering, computational and data sciences. Its integrated, multidisciplinary coverage supports progress from basic research to clinical translation.

**A hub for collaboration and communication across disciplines.** _Cancer Innovation_ unites researchers and clinicians from diverse medical subspecialities, providing opportunities to exchange, collaborate, and explore together.

**A high-quality platform for guidelines on clinical decisions.** Led by the China National Cancer Center, the editors ensure authentic statistics, consensus, and guidelines for clinical reference. _Cancer Innovation_ combines professional resources to close the shortcomings in the management of oncological comorbidities.

[Read the aims and scope](/page/journal/27709183/homepage/productinformation.html)

* * *

### News

We are glad to announce that _Cancer Innovation_ has been indexed by Web of Science, Scopus, DOAJ, PMC (PubMed Center) and CAS: Chemical Abstract Service!

[Skip slideshow](#afterSlideshow-d1q)

### Special issue call for papers

#### [Onco-cardiology](/page/journal/27709183/homepage/call-for-papers/si-oncocardiology)

**Submission deadline: 30 April 2024**

In-depth research on risk factors and interventions for cardiovascular diseases shared with tumors, cardiovascular complications caused by anti-tumor therapy, cardiac tumors and tumors combined with cardiovascular diseases are needed to improve the quality of life and prognosis of tumor patients. This special issue aims at collecting advanced **Original Articles, Reviews, Meta-Analysis, Study Protocols, Clinical Guidelines, Technical Reports, Case Reports, Commentaries, News, and Editorials** on onco-cardiology and related fields.

**Guest editor:** Professor Tong Liu, _Tianjin Key Laboratory of Ionic-Molecular Function of Cardiovascular disease, Department of Cardiology, Tianjin Institute of Cardiology, Second Hospital of Tianjin Medical University_

**Submission Site:** [ScholarOne System](https://mc.manuscriptcentral.com/cancerinnovation) (please select for inclusion in 'Onco-cardiology')

For any inquiries about the appropriateness of contribution topics, please contact Prof. Tong Liu via [\[email protected\]](/cdn-cgi/l/email-protection#b7dbdec2c3d8d9d0d3d8d4f786858199d4d8da). If you need any assistance for submission, feel free to contact the Editorial Office via [\[email protected\]](/cdn-cgi/l/email-protection#a0c3c1cec3c5d2c9cececfd6c1d4c9cfcee0d4d5d08ed4d3c9cec7c8d5c18ec5c4d5).

### Editors’ Choice

[![](/pb-assets/assets/27709183/cai2.108-fig-1715356217.jpg)](https://onlinelibrary.wiley.com/doi/10.1002/cai2.108)[Cardiovascular disease burden in patients with urological cancers: The new discipline of uro-cardio-oncology](https://onlinelibrary.wiley.com/doi/10.1002/cai2.108)

Treatment-induced cardiovascular toxicity is linked to ADT, VEGFR-TKIs, ICIs, and chemotherapy. We propose the new discipline of uro-cardio-oncology to address the relationship between cardiovascular disease and urological cancers. ADT, androgen deprivation therapy; ICI, immune checkpoint inhibitor; VEGFR-TKI, vascular endothelial growth factor receptor tyrosine kinase inhibitor.

[![](/pb-assets/assets/27709183/cai2.113-fig-1715356218.jpg)](https://onlinelibrary.wiley.com/doi/10.1002/cai2.113)[Improvement of histone deacetylase inhibitor efficacy by SN38 through TWIST1 suppression in synovial sarcoma](https://onlinelibrary.wiley.com/doi/10.1002/cai2.113)

Histone deacetylase (HDAC) inhibitor (HDACi) is a potent antitumor drug candidate for synovial sarcoma (SS) treatment. Twist1 expression often causes drug resistance. SN38 overcomes Twist1-induced drug resistance for HDACi through the suppression of Twist1 protein expression in SS cells.

[More](https://onlinelibrary.wiley.com/page/journal/27709183/homepage/editors_highlights)

### Editors’ Choice

[![](/pb-assets/assets/27709183/cai2111-fig-1715355778.jpg)](https://onlinelibrary.wiley.com/doi/10.1002/cai2.111)[Clinical Practice Guidelines for Full-Cycle Standardized Management of Bone Health in Breast Cancer Patients](https://onlinelibrary.wiley.com/doi/10.1002/cai2.111)

This guideline has been developed by the Breast Cancer Expert Committee of the National Cancer Quality Control Center. The experts involved in this guideline have thoroughly examined the comprehensive management of bone health in breast cancer, aiming to establish a reference framework for managing bone health and standardizing the diagnosis and treatment of breast cancer patients.

[![](/pb-assets/assets/27709183/cai2.64-fig-1715355774.jpg)](https://onlinelibrary.wiley.com/doi/10.1002/cai2.64)[A comprehensive review on 3-D cancer models for drug screening and translational research](https://onlinelibrary.wiley.com/doi/10.1002/cai2.64)

This review discusses the vast valuable importance of Tumor microenvironment (TME) recapitulation in cancer research prioritizing individual roles of TME elements in the histopathology of cancer. Further, the review broadly describes of few of the recently developed 3D models that have their main focus restricted to drug development and their screening and/or implications of the approach in preclinical as well as translational research.

[More](https://onlinelibrary.wiley.com/page/journal/27709183/homepage/editors_highlights)

### Editors’ Choice

[Survival nomograms for simultaneous resection of primary and hepatic lesions without neoadjuvant chemotherapy in patients with resectable colorectal liver metastasis](https://onlinelibrary.wiley.com/doi/10.1002/cai2.45)

There is no consensus on the prognosis for patients with resectable colorectal liver metastasis (CRLM) who undergo simultaneous resection of primary and hepatic lesions without neoadjuvant chemotherapy (NAC). We aim to construct the nomogram models to investigate the prognosis of patients with resectable CRLM undergoing simultaneous resection of primary and hepatic lesions without NAC.

[Resveratrol activation of SIRT1/MFN2 can improve mitochondria function, alleviating doxorubicin-induced myocardial injury](https://onlinelibrary.wiley.com/doi/10.1002/cai2.64)

There is no consensus on the prognosis for patients with resectable colorectal liver metastasis (CRLM) who undergo simultaneous resection of primary and hepatic lesions without neoadjuvant chemotherapy (NAC). We aim to construct the nomogram models to investigate the prognosis of patients with resectable CRLM undergoing simultaneous resection of primary and hepatic lesions without NAC.

[Global trends of cancer: The role of diet, lifestyle, and environmental factors](https://onlinelibrary.wiley.com/doi/10.1002/cai2.76)

The age-standardized cancer incidence rate data for the selected countries indicate a great areal variation and different global trends for each type of cancer. Analysis of the worldwide statistical data regionally for cancer incidence rates for certain cancers meaningfully correlate with diet, lifestyle, and environmental factors.

[More](https://onlinelibrary.wiley.com/page/journal/27709183/homepage/editors_highlights)

### Editors’ Choice

[![](/pb-assets/assets/27709183/cai275-gra-0001-m-1688124229.jpg)](https://onlinelibrary.wiley.com/doi/10.1002/cai2.75)[PD-1/L1 inhibitors can improve but not replace chemotherapy for advanced urothelial carcinoma: A systematic review and network meta-analysis](https://onlinelibrary.wiley.com/doi/10.1002/cai2.75)

The efficacy of programmed cell death-1/ligand 1 inhibitors in patients with advanced urothelial carcinoma is approximate to first-line platinum-based chemotherapy, and programmed cell death-1/ligand 1 inhibitors are safer than first- and second-line chemotherapy and have a broader prospect for use in combination therapy.

[![](/pb-assets/assets/27709183/cai243-gra-0001-m-1688124232.jpg)](https://onlinelibrary.wiley.com/doi/10.1002/cai2.65)[Third-line or above anlotinib in relapsed and refractory small cell lung cancer patients with brain metastases: A post hoc analysis of ALTER1202, a randomized, double-blind phase 2 study](https://onlinelibrary.wiley.com/doi/10.1002/cai2.43)

In this post hoc analysis of a multicenter, randomized, double-blind, placebo-controlled trial, anlotinib demonstrated a potential survival benefit in small cell lung cancer (SCLC) with brain metastases (BM) compared with placebo, with manageable toxicity. Anlotinib significantly prolonged median progression-free survival (PFS) (hazard ratio \[HR\] = 0.15, 95% CI: 0.04–0.51; _p_ = 0.0005) and median OS (HR = 0.26, 95% CI: 0.09–0.73; _p_ = 0.0061) in SCLC patients with BM.

[More](https://onlinelibrary.wiley.com/page/journal/27709183/homepage/editors_highlights)

### Editors’ Choice

[Advances in the treatment of solid tumors in children and adolescents](https://onlinelibrary.wiley.com/doi/10.1002/cai2.66)

![](/pb-assets/assets/27709183/cai266-gra-0001-m-1683188686.jpg)

The tumor is one of the threats to children and adolescents' life and health, causing death and reduced quality of life. But there are few studies on them. Improving the survival rate and survival time of patients is our common goal. We reviewed the literature in recent years, and summarized the new progress achieved in terms of chemotherapy regimens, molecular targeted drugs, and immunotherapy, to provide new ideas for the treatment of tumors in children and adolescents.

[More](https://onlinelibrary.wiley.com/page/journal/27709183/homepage/editors_highlights)

### Editors’ Choice

[![](/pb-assets/assets/27709183/cai259-gra-0001-m-1683188681.jpg)](https://onlinelibrary.wiley.com/doi/10.1002/cai2.59)[Progress in phase III clinical trials of molecular targeted therapy and immunotherapy for glioblastoma](https://onlinelibrary.wiley.com/doi/10.1002/cai2.59)

A wide variety of targeted drugs and immunotherapies are tested for patients with glioblastoma, but not all of these drugs are effective, and only a few of these trials have prolonged the lives of patients. We summarize the phase III clinical trial of target therapy and inmmunotherapy for glioblastoma and discuss the challenge faced contemporaneously and prospects of targeted drugs and immunotherapy in the future.

[![](/pb-assets/assets/27709183/cai265-gra-0001-m-1683188683.jpg)](https://onlinelibrary.wiley.com/doi/10.1002/cai2.65)[High BRCA1 expression is an independent prognostic biomarker in LUAD and correlates with immune infiltration](https://onlinelibrary.wiley.com/doi/10.1002/cai2.65)

Lung adenocarcinoma (LUAD) patients with elevated breast cancer susceptibility gene 1 (BRCA1) expression had markedly worse overall survival and progression-free survival compared to those with reduced BRCA1 levels. In contrast, BRCA1 expression did not correlate with survival outcomes in squamous cell carcinoma patients. The overexpression of BRCA1 was an independent risk factor for LUAD and was indicative of an immune-suppressive tumor microenvironment.

[More](https://onlinelibrary.wiley.com/page/journal/27709183/homepage/editors_highlights)

### Editors’ Choice

[![](/pb-assets/assets/27709183/cai246-gra-0001-m-1678091050.jpg)](https://onlinelibrary.wiley.com/doi/10.1002/cai2.33)[Advances in medical treatment of breast cancer in 2022](https://onlinelibrary.wiley.com/doi/full/10.1002/cai2.46)

This article summarizes the annual progress of breast cancer chemotherapy, targeted therapy, endocrine therapy and immunotherapy in 2022, providing valuable information for future research to better guide individualized treatment of breast cancer, thereby improving the prognosis and quality of life of breast cancer patients.

[![](/pb-assets/assets/27709183/cai255-gra-0001-m-1678091051.jpg)](https://onlinelibrary.wiley.com/doi/10.1002/cai2.37)[Recent advances in immunotherapy for lung cancer](https://onlinelibrary.wiley.com/doi/10.1002/cai2.55)

In recent years, immunotherapy has gradually moved from the back line to the front line, from advanced to early patients. This article focuses on the latest developments in perioperative and advanced lung cancer immunotherapy, discusses the problems and challenges at the current stage, and explores new directions for future development.

[More](https://onlinelibrary.wiley.com/page/journal/27709183/homepage/editors_highlights)

## On the Cover

![](/pb-assets/assets/27709183/cai2.v1.3.cover-1667798157.png)**Editor's Choice**:

1\. [Circular RNAs: Biomarkers of cancer](https://onlinelibrary.wiley.com/doi/10.1002/cai2.28)

This study demonstrates that circular RNAs (circRNAs) have great potential as biomarkers for cancer diagnosis and prognosis, which is highlighted by their detectability in tissues and fluid biopsy samples.

2\. [Research progress in the establishment of pancreatic cancer models and preclinical applications](https://onlinelibrary.wiley.com/doi/10.1002/cai2.31)

In recent years, some novel mouse pancreatic cancer models (including orthotopic and heterotopic models) which can show more realistic features of human pancreatic cancer and contribute to the validation of drugs and targets with therapeutic potential in pancreatic cancer have been established by using different technical means.

[More](https://onlinelibrary.wiley.com/toc/27709183/2022/1/3)

## Meet the Editor-in-Chief

![](/pb-assets/assets/27709183/1.马飞-1641527388.png)

**Fei Ma** _, National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China_

Fei Ma is the chief physician & director of Internal Therapy Center of Cancer Hospital, principal investigator of State Key Laboratory of Molecular Oncology, Chinese Academy of Medical Sciences. He has long been dedicated to basic, clinical and translational research in oncology, focusing on interdisciplinary studies. In the past 5 years, he has published more than 50 peer review papers as first/corresponding author, especially in _Lancet Oncology_, _Journal of Clinical Oncology and Nature Communication_.

## Why publish in Cancer Innovation?

- **Your research will be free to access**, making it available to read, download and share with ease.
- **Quality and impactful research** governed by an international and distinguished editorial board.
- Publish open access at **no cost to you**\- fees are waived from 2022-2024.
- An official journal of the **Boao Cancer Innovation Institute**, devoted to innovative and significant research in basic research and clinical oncology, and published on behalf of Tsinghua University Press.
- **Save time formatting** your manuscript with **[free formatting submission](https://authorservices.wiley.com/author-resources/Journal-Authors/Prepare/free-format-submission.html).**

[Read the aims and scope](/page/journal/27709183/homepage/productinformation.html)

[![](/pb-assets/assets/17530407/p3-1625469200447.png)](/action/doUpdateAlertSettings?action=addJournal&journalCode=27709183)

Get the latest research from _Cancer Innovation_. Create a FREE Wiley Online Library account and register to receive Content Alerts today!

- Receive personalized alerts at a pace that suits you.
- Keep track of a paper of interest with citation alerts.
- Save content to easily manage your reading list.
- Save searches for instant review later.

[Register for Content Alerts](/action/doUpdateAlertSettings?action=addJournal&journalCode=27709183)

#### _Cancer Innovation_ adopts free format submission

With **[free format submission](https://authorservices.wiley.com/author-resources/Journal-Authors/Prepare/free-format-submission.html)**, you don’t need to worry about following formatting requirements during submission. We know your time is valuable and should be spent on your research, not re-typing reference lists.

[![Cancer Innovation Free format submission](/pb-assets/assets/24750360/FFS-1634130741020.jpg)](https://mc.manuscriptcentral.com/healthcarescience)

[![Cancer Innovation open access](/pb-assets/assets/24750360/OA_Metrics_April2023_blue-1686550914.png)](https://authorservices.wiley.com/open-research/open-access/index.html "Health Care Science open access")

## Articles

- [Most Recent](#pane-01cbe741-499a-4611-874e-1061f1f4679e01)
- [Most Cited](#pane-01cbe741-499a-4611-874e-1061f1f4679e11)
- [Most Read](#pane-01cbe741-499a-4611-874e-1061f1f4679e21)

ORIGINAL ARTICLE

Open access

[**A pan‐cancer analysis of Wnt family member 7B in human cancers**](/doi/full/10.1002/cai2.139)

[Rui Wang](/authored-by/Wang/Rui), [Ni-sha Wu](/authored-by/Wu/Ni%E2%80%90sha), [Li Wang](/authored-by/Wang/Li), [Zhi-zhao Zhang](/authored-by/Zhang/Zhi%E2%80%90zhao), [Cheng-fang Wang](/authored-by/Wang/Cheng%E2%80%90fang), [Yan Wang](/authored-by/Wang/Yan), [Yan Liang](/authored-by/Liang/Yan), [Yi Zhang](/authored-by/Zhang/Yi), [Xiao-wei Qi](/authored-by/Qi/Xiao%E2%80%90wei),

- First Published:  9 September 2024

### Graphical Abstract

[![A pan-cancer analysis of Wnt family member 7B in human cancers Issue 5, 2024](/cms/asset/d97313f8-1d98-476b-b7b8-cf6588de9315/cai2139-gra-0001-m.jpg)](/cms/asset/d97313f8-1d98-476b-b7b8-cf6588de9315/cai2139-gra-0001-m.jpg "Link to full-size graphical abstract")

Previous studies have confirmed the important role of Wnt family member 7B (Wnt7B) in the formation of various cancers such as breast, pancreatic, and gastric cancers; however, studies on the specificity of Wnt7B in tumors are limited to certain specific cancers, and systematic pan-cancer studies are lacking, and whether it can be used as a potential biomarker for cancer diagnosis and prognosis remains to be determined. We used bioinformatics techniques and immunohistochemistry (IHC) to observe its expression and function in cancerous and paracancerous tissues of various tumors. Finally, we found that Wnt7B exhibited significant upregulation in the majority of cancer cases，at the same time，Wnt7B affects cancer prognosis through regulating tumor microenvironment，immune infiltration, tumor stemness, and other aspects, which suggests that Wnt7B can be a new cancer prognostic indicator and therapeutic target, and also the pharmacosensitivity analysis related to Wnt7B and cancer therapy can provide some help for clinical precision treatment.

- [Abstract](/doi/abs/10.1002/cai2.139 "Abstract")
- [Full text](/doi/full/10.1002/cai2.139 "Full text")
- [PDF](/doi/epdf/10.1002/cai2.139 "ePDF")
- [References](/doi/full/10.1002/cai2.139#reference "References")
- [Request permissions](https://onlinelibrary.wiley.com/action/rightsLink?doi=10.1002%2Fcai2.139&mode= "Request permissions")

CLINICAL GUIDELINE

Open access

[**Chinese expert consensus on an innovative patient‐centered approach to diagnosis and treatment of cancer**](/doi/full/10.1002/cai2.137)

[Hongnan Mo](/authored-by/Mo/Hongnan), [Ruiqi Zhong](/authored-by/Zhong/Ruiqi), [Fei Ma](/authored-by/Ma/Fei),

- First Published:  30 July 2024

### Graphical Abstract

[![Chinese expert consensus on an innovative patient-centered approach to diagnosis and treatment of cancer Issue 5, 2024](/cms/asset/ce97d75f-aa55-4166-99db-9442528d4c3a/cai2137-gra-0001-m.jpg)](/cms/asset/ce97d75f-aa55-4166-99db-9442528d4c3a/cai2137-gra-0001-m.jpg "Link to full-size graphical abstract")

Patient-centered care (PCC) is a developing and innovative approach to the diagnosis and treatment of malignant tumors, aiming to improve the experience of cancer patients throughout their disease management. This consensus provides a clear definition of PCC, outlines its main components as observed in real-world practice, delves into the implementation of PCC, and explores its potential benefits.

- [Abstract](/doi/abs/10.1002/cai2.137 "Abstract")
- [Full text](/doi/full/10.1002/cai2.137 "Full text")
- [PDF](/doi/epdf/10.1002/cai2.137 "ePDF")
- [References](/doi/full/10.1002/cai2.137#reference "References")
- [Request permissions](https://onlinelibrary.wiley.com/action/rightsLink?doi=10.1002%2Fcai2.137&mode= "Request permissions")

REVIEW

Open access

[**Explainable artificial intelligence in breast cancer detection and risk prediction: A systematic scoping review**](/doi/full/10.1002/cai2.136)

[Amirehsan Ghasemi](/authored-by/Ghasemi/Amirehsan), [Soheil Hashtarkhani](/authored-by/Hashtarkhani/Soheil), [David L. Schwartz](/authored-by/Schwartz/David+L.), [Arash Shaban-Nejad](/authored-by/Shaban%E2%80%90Nejad/Arash),

- First Published:  3 July 2024

### Graphical Abstract

[![Explainable artificial intelligence in breast cancer detection and risk prediction: A systematic scoping review Issue 5, 2024](/cms/asset/7dfb6e96-356c-48af-918c-f2fcbeb3066d/cai2136-gra-0001-m.jpg)](/cms/asset/7dfb6e96-356c-48af-918c-f2fcbeb3066d/cai2136-gra-0001-m.jpg "Link to full-size graphical abstract")

This systematic review is carried out using the preferred reporting items on systematic reviews and meta-analysis (PRISMA) guideline in three steps as follows:



- **Step 1:**
Identifying studies (total of 193 studies were initially included).

- **Step 2:**
Selecting the studies (total of 30 articles met the inclusion criteria for our comprehensive review).

- **Step 3:**
Data extraction and summarization (A data extraction form was developed in Google Sheets, consisting of eight variables, including Authors, Year, the aim of the study (Objective), Data set(s), Data type, Important features, type of artificial intelligence (machine learning or deep learning), and the Explained model. Two reviewers (Amirehsan Ghasemi and Soheil Hashtarkhani) extracted data from all included articles, and any disagreement was resolved by consensus.


- [Abstract](/doi/abs/10.1002/cai2.136 "Abstract")
- [Full text](/doi/full/10.1002/cai2.136 "Full text")
- [PDF](/doi/epdf/10.1002/cai2.136 "ePDF")
- [References](/doi/full/10.1002/cai2.136#reference "References")
- [Request permissions](https://onlinelibrary.wiley.com/action/rightsLink?doi=10.1002%2Fcai2.136&mode= "Request permissions")

ORIGINAL ARTICLE

Open access

[**Radiomics models to predict bone marrow metastasis of neuroblastoma using CT**](/doi/full/10.1002/cai2.135)

[Xiong Chen](/authored-by/Chen/Xiong), [Qinchang Chen](/authored-by/Chen/Qinchang), [Yuanfang Liu](/authored-by/Liu/Yuanfang), [Ya Qiu](/authored-by/Qiu/Ya), [Lin Lv](/authored-by/Lv/Lin), [Zhengtao Zhang](/authored-by/Zhang/Zhengtao), [Xuntao Yin](/authored-by/Yin/Xuntao), [Fangpeng Shu](/authored-by/Shu/Fangpeng),

- First Published:  28 June 2024

### Graphical Abstract

[![Radiomics models to predict bone marrow metastasis of neuroblastoma using CT Issue 5, 2024](/cms/asset/5cc3adc1-46be-4dd6-9467-37321cea2900/cai2135-gra-0001-m.jpg)](/cms/asset/5cc3adc1-46be-4dd6-9467-37321cea2900/cai2135-gra-0001-m.jpg "Link to full-size graphical abstract")

Information from 187 patients with neuroblastoma were retrospectively collected and randomly divided into the training and validation sets. Radiomics features were extracted from computed tomography to build noninvasive radiomics models. We attempted 13 machine learning algorithms and eventually chose three best-performed models.

- [Abstract](/doi/abs/10.1002/cai2.135 "Abstract")
- [Full text](/doi/full/10.1002/cai2.135 "Full text")
- [PDF](/doi/epdf/10.1002/cai2.135 "ePDF")
- [References](/doi/full/10.1002/cai2.135#reference "References")
- [Request permissions](https://onlinelibrary.wiley.com/action/rightsLink?doi=10.1002%2Fcai2.135&mode= "Request permissions")

ORIGINAL ARTICLE

Open access

[**High‐fat‐diet‐induced obesity promotes simultaneous progression of lung cancer and atherosclerosis in apolipoprotein E‐knockout mice**](/doi/full/10.1002/cai2.127)

[Yihao Wang](/authored-by/Wang/Yihao), [Kaixin Yan](/authored-by/Yan/Kaixin), [Han Duan](/authored-by/Duan/Han), [Ning Tao](/authored-by/Tao/Ning), [Shaoning Zhu](/authored-by/Zhu/Shaoning), [Yuning Zhang](/authored-by/Zhang/Yuning), [Yonggang You](/authored-by/You/Yonggang), [Zhen Zhang](/authored-by/Zhang/Zhen), [Hua Wang](/authored-by/Wang/Hua), [Shunying Hu](/authored-by/Hu/Shunying),

- First Published:  5 June 2024

### Graphical Abstract

[![High-fat-diet-induced obesity promotes simultaneous progression of lung cancer and atherosclerosis in apolipoprotein E-knockout mice Issue 4, 2024](/cms/asset/5c466312-5457-4997-862a-509b6e06a9bf/cai2127-gra-0001-m.jpg)](/cms/asset/5c466312-5457-4997-862a-509b6e06a9bf/cai2127-gra-0001-m.jpg "Link to full-size graphical abstract")

Clinical studies showed that atherosclerotic cardiovascular disease (ASCVD) and cancer often coexist in the same individual. The study first showed that obesity could promote atherosclerosis burden as well as promote tumorigenesis and metastasis of lung cancer in the same individual mice. The results showed that obesity could contribute to the coexistence of atherosclerosis and lung cancer; so, screening both ASCVD and lung cancer would be significant in obese patients. LOX-1-related pathway likely was a significant contributor to the coexistence of atherosclerosis and lung cancer in the same individual. LOX-1 could be a target for the management of ASCVD and lung cancer in obese patients.

- [Abstract](/doi/abs/10.1002/cai2.127 "Abstract")
- [Full text](/doi/full/10.1002/cai2.127 "Full text")
- [PDF](/doi/epdf/10.1002/cai2.127 "ePDF")
- [References](/doi/full/10.1002/cai2.127#reference "References")
- [Request permissions](https://onlinelibrary.wiley.com/action/rightsLink?doi=10.1002%2Fcai2.127&mode= "Request permissions")

[More articles](/action/doSearch?SeriesKey=27709183&sortBy=Earliest "More articles")

Articles with the most citations published in the Last 2 Years according to CrossRef.
The citation counts listed reflect the total number of all citations to date.

ORIGINAL ARTICLE

Open access

[**Prediction of death rates for cardiovascular diseases and cancers**](/doi/10.1002/cai2.47 "Prediction of death rates for cardiovascular diseases and cancers")

[Oleg Gaidai](/authored-by/Gaidai/Oleg), [Yihan Xing](/authored-by/Xing/Yihan), [Rajiv Balakrishna](/authored-by/Balakrishna/Rajiv), [Jiayao Sun](/authored-by/Sun/Jiayao), [Xiaolong Bai](/authored-by/Bai/Xiaolong),

- [Cancer Innovation](/journal/27709183)
- Pages: 140-147
- First Published:  9 February 2023

### Graphical Abstract

[![Prediction of death rates for cardiovascular diseases and cancers Issue 2, 2023](/cms/asset/e1696cca-f868-4c47-835e-0f06ce6579ec/cai247-gra-0001-m.jpg)](/cms/asset/e1696cca-f868-4c47-835e-0f06ce6579ec/cai247-gra-0001-m.jpg "Link to full-size graphical abstract")

A novel health system reliability method has been developed and applied to cardio and cancer death rate data. Accurate disease multiregional prediction is done.

- [Abstract](/doi/abs/10.1002/cai2.47 "Abstract")
- [Full text](/doi/full/10.1002/cai2.47 "Full text")
- [PDF](/doi/epdf/10.1002/cai2.47 "EPDF")
- [References](/doi/full/10.1002/cai2.47#reference "References")
- [Request permissions](https://onlinelibrary.wiley.com/action/rightsLink?doi=10.1002%2Fcai2.47&mode= "Request permissions")

REVIEW

Open access

[**Advances in medical treatment of breast cancer in 2022**](/doi/10.1002/cai2.46 "Advances in medical treatment of breast cancer in 2022")

[Jingtong Zhai](/authored-by/Zhai/Jingtong), [Yun Wu](/authored-by/Wu/Yun), [Fei Ma](/authored-by/Ma/Fei), [Virginia Kaklamani](/authored-by/Kaklamani/Virginia), [Binghe Xu](/authored-by/Xu/Binghe),

- [Cancer Innovation](/journal/27709183)
- Pages: 1-17
- First Published:  21 February 2023

### Graphical Abstract

[![Advances in medical treatment of breast cancer in 2022 Issue 1, 2023](/cms/asset/9d9de681-3ae7-4715-b91b-6e6d795e6ac8/cai246-gra-0001-m.jpg)](/cms/asset/9d9de681-3ae7-4715-b91b-6e6d795e6ac8/cai246-gra-0001-m.jpg "Link to full-size graphical abstract")

This article summarizes the annual progress of breast cancer chemotherapy, targeted therapy, endocrine therapy and immunotherapy in 2022, providing valuable information for future research to better guide individualized treatment of breast cancer, thereby improving the prognosis and quality of life of breast cancer patients.

- [Abstract](/doi/abs/10.1002/cai2.46 "Abstract")
- [Full text](/doi/full/10.1002/cai2.46 "Full text")
- [PDF](/doi/epdf/10.1002/cai2.46 "EPDF")
- [References](/doi/full/10.1002/cai2.46#reference "References")
- [Request permissions](https://onlinelibrary.wiley.com/action/rightsLink?doi=10.1002%2Fcai2.46&mode= "Request permissions")

REVIEW

Open access

[**Radiotherapy, photodynamic therapy, and cryoablation‐induced abscopal effect: Challenges and future prospects**](/doi/10.1002/cai2.53 "Radiotherapy, photodynamic therapy, and cryoablation‐induced abscopal effect: Challenges and future prospects")

[Sadik Ali Mohammad](/authored-by/Ali+Mohammad/Sadik), [Arshadul Hak](/authored-by/Hak/Arshadul), [Sunil V. Pogu](/authored-by/Pogu/Sunil+V.), [Aravind K. Rengan](/authored-by/Rengan/Aravind+K.),

- [Cancer Innovation](/journal/27709183)
- Pages: 323-345
- First Published:  23 February 2023

### Graphical Abstract

[![Radiotherapy, photodynamic therapy, and cryoablation-induced abscopal effect: Challenges and future prospects Issue 5, 2023](/cms/asset/1e8aa043-569e-46fe-bacf-be2f103bd8f2/cai253-gra-0001-m.jpg)](/cms/asset/1e8aa043-569e-46fe-bacf-be2f103bd8f2/cai253-gra-0001-m.jpg "Link to full-size graphical abstract")

- Primary or local tumor ablation following local therapy (such as radiotherapy, photodynamic therapy, and cryoablation) causes the release of damage-associated molecular proteins and tumor-associated antigens, which are then presented to dendritic cells (antigen-presenting cells) and results in the development of a systemic antitumor immune response, or “abscopal effect.”


- However, the immune-suppressive tumor microenvironment blocks the antitumor immune response through several mechanisms, including the immune checkpoint mechanism (programmed death-1, programmed death ligand-1, and cytotoxic T lymphocyte-associated protein-4) and the overexpression of immunosuppressive cells myeloid-derived T-regulatory cells, myeloid-derived suppressor cells, and tumor-associated macrophages, and so on.


- The use of immunotherapy can be used to treat these immune suppression mechanisms. Therefore, local therapy and immunotherapy combined have been proven to provide an effective abscopal impact. Immune-related adverse effects, however, can result from immunotherapy. Determining the precise sort of immunosuppressive mechanism and using specialized immunotherapy can combat these drawbacks. This can be achieved by using a nanotheranostic method, in which nanoparticles are loaded with prognostic biomarkers and predictive biomarkers, and to develop a strategy that could be multifaceted and address all potential obstacles that slow the abscopal impact.


- [Abstract](/doi/abs/10.1002/cai2.53 "Abstract")
- [Full text](/doi/full/10.1002/cai2.53 "Full text")
- [PDF](/doi/epdf/10.1002/cai2.53 "EPDF")
- [References](/doi/full/10.1002/cai2.53#reference "References")
- [Request permissions](https://onlinelibrary.wiley.com/action/rightsLink?doi=10.1002%2Fcai2.53&mode= "Request permissions")

REVIEW

Open access

[**Circular RNAs: Biomarkers of cancer**](/doi/10.1002/cai2.28 "Circular RNAs: Biomarkers of cancer")

[Jingyi Cui](/authored-by/Cui/Jingyi), [Meng Chen](/authored-by/Chen/Meng), [Lanxin Zhang](/authored-by/Zhang/Lanxin), [Sida Huang](/authored-by/Huang/Sida), [Fei Xiao](/authored-by/Xiao/Fei), [Lihui Zou](/authored-by/Zou/Lihui),

- [Cancer Innovation](/journal/27709183)
- Pages: 197-206
- First Published:  21 September 2022

### Graphical Abstract

[![Circular RNAs: Biomarkers of cancer Issue 3, 2022](/cms/asset/d9c428aa-0503-4287-bcda-154c44ac20fe/cai228-gra-0001-m.jpg)](/cms/asset/d9c428aa-0503-4287-bcda-154c44ac20fe/cai228-gra-0001-m.jpg "Link to full-size graphical abstract")

This study demonstrates that circular RNAs (circRNAs) have great potential as biomarkers for cancer diagnosis and prognosis, which is highlighted by their detectability in tissues and fluid biopsy samples. CircRNAs may act as biomarkers in cancers including glioma, bladder cancer, breast cancer, gastric cancer, hepatocellular carcinoma, colorectal cancer, lung cancer, kidney cancer, pancreatic cancer, and leukemia.

- [Abstract](/doi/abs/10.1002/cai2.28 "Abstract")
- [Full text](/doi/full/10.1002/cai2.28 "Full text")
- [PDF](/doi/epdf/10.1002/cai2.28 "EPDF")
- [References](/doi/full/10.1002/cai2.28#reference "References")
- [Request permissions](https://onlinelibrary.wiley.com/action/rightsLink?doi=10.1002%2Fcai2.28&mode= "Request permissions")

REVIEW

Open access

[**Annual progress of clinical research on targeted therapy for nonsmall cell lung cancer in 2022**](/doi/10.1002/cai2.56 "Annual progress of clinical research on targeted therapy for nonsmall cell lung cancer in 2022")

[Yan Huang](/authored-by/Huang/Yan), [Li Zhang](/authored-by/Zhang/Li),

- [Cancer Innovation](/journal/27709183)
- Pages: 25-35
- First Published:  1 March 2023

### Graphical Abstract

[![Annual progress of clinical research on targeted therapy for nonsmall cell lung cancer in 2022 Issue 1, 2023](/cms/asset/090f7bcf-2a7a-42ca-8e79-9da9677a7d0b/cai256-gra-0001-m.jpg)](/cms/asset/090f7bcf-2a7a-42ca-8e79-9da9677a7d0b/cai256-gra-0001-m.jpg "Link to full-size graphical abstract")

The two most frequent alterations in nonsmall cell lung cancer patients were epidermal growth factor receptor and KRAS mutations, accounting for 10%–40% and 25%–32%, respectively. Although the incidence rate is relatively low, other gene mutations including anaplastic lymphoma kinase fusion, MET ex14+, ROS1 fusion, KRAS mutation, and so forth, are also crucial to the survival of patients, and numerous significant pharmacological advances have been produced so far.

- [Abstract](/doi/abs/10.1002/cai2.56 "Abstract")
- [Full text](/doi/full/10.1002/cai2.56 "Full text")
- [PDF](/doi/epdf/10.1002/cai2.56 "EPDF")
- [References](/doi/full/10.1002/cai2.56#reference "References")
- [Request permissions](https://onlinelibrary.wiley.com/action/rightsLink?doi=10.1002%2Fcai2.56&mode= "Request permissions")

REVIEW

Open access

[**Global trends of cancer: The role of diet, lifestyle, and environmental factors**](/doi/10.1002/cai2.76 "Global trends of cancer: The role of diet, lifestyle, and environmental factors")

[Hassan Bahrami](/authored-by/Bahrami/Hassan), [Majid Tafrihi](/authored-by/Tafrihi/Majid),

- [Cancer Innovation](/journal/27709183)
- Pages: 290-301
- First Published:  25 July 2023

### Graphical Abstract

[![Global trends of cancer: The role of diet, lifestyle, and environmental factors Issue 4, 2023](/cms/asset/30ccb41d-fdfe-4080-9fd3-53d12666ef05/cai276-gra-0001-m.jpg)](/cms/asset/30ccb41d-fdfe-4080-9fd3-53d12666ef05/cai276-gra-0001-m.jpg "Link to full-size graphical abstract")

The age-standardized cancer incidence rate data for the selected countries indicate a great areal variation and different global trends for each type of cancer. Analysis of the worldwide statistical data regionally for cancer incidence rates for certain cancers meaningfully correlate with diet, lifestyle, and environmental factors.

- [Abstract](/doi/abs/10.1002/cai2.76 "Abstract")
- [Full text](/doi/full/10.1002/cai2.76 "Full text")
- [PDF](/doi/epdf/10.1002/cai2.76 "EPDF")
- [References](/doi/full/10.1002/cai2.76#reference "References")
- [Request permissions](https://onlinelibrary.wiley.com/action/rightsLink?doi=10.1002%2Fcai2.76&mode= "Request permissions")

REVIEW

Open access

[**Applications of digital Medicine in oncology: Prospects and challenges**](/doi/10.1002/cai2.37 "Applications of digital Medicine in oncology: Prospects and challenges")

[Hewei Ge](/authored-by/Ge/Hewei), [Lixi Li](/authored-by/Li/Lixi), [Di Zhang](/authored-by/Zhang/Di), [Fei Ma](/authored-by/Ma/Fei),

- [Cancer Innovation](/journal/27709183)
- Pages: 285-292
- First Published:  4 December 2022

### Graphical Abstract

[![Applications of digital Medicine in oncology: Prospects and challenges Issue 4, 2022](/cms/asset/544b0446-0534-4881-a9ab-6cf55182942b/cai237-gra-0001-m.jpg)](/cms/asset/544b0446-0534-4881-a9ab-6cf55182942b/cai237-gra-0001-m.jpg "Link to full-size graphical abstract")

This review summarizes the applications of digital medicine in cancer prevention, screening, diagnosis, and treatment, as well as clinical trials. Integrating digital medicine into clinical practice has the advantages of broader applicability, greater cost-effectiveness, better accessibility, and improved diagnostic and therapeutic performance.

- [Abstract](/doi/abs/10.1002/cai2.37 "Abstract")
- [Full text](/doi/full/10.1002/cai2.37 "Full text")
- [PDF](/doi/epdf/10.1002/cai2.37 "EPDF")
- [References](/doi/full/10.1002/cai2.37#reference "References")
- [Request permissions](https://onlinelibrary.wiley.com/action/rightsLink?doi=10.1002%2Fcai2.37&mode= "Request permissions")

ORIGINAL ARTICLE

Open access

[**An integrated analysis of _C5AR2_ related to malignant properties and immune infiltration of gliomas**](/doi/10.1002/cai2.29 "An integrated analysis of <i>C5AR2</i> related to malignant properties and immune infiltration of gliomas")

[Chengying Huang](/authored-by/Huang/Chengying), [Ouwen Qiu](/authored-by/Qiu/Ouwen), [Chaofu Mao](/authored-by/Mao/Chaofu), [Zhicheng Hu](/authored-by/Hu/Zhicheng), [Shanqiang Qu](/authored-by/Qu/Shanqiang),

- [Cancer Innovation](/journal/27709183)
- Pages: 240-251
- First Published:  5 October 2022

### Graphical Abstract

[![An integrated analysis of C5AR2 related to malignant properties and immune infiltration of gliomas Issue 3, 2022](/cms/asset/fd2df823-8cc0-414e-9f7c-c63d4457e78d/cai229-gra-0001-m.jpg)](/cms/asset/fd2df823-8cc0-414e-9f7c-c63d4457e78d/cai229-gra-0001-m.jpg "Link to full-size graphical abstract")

C5AR2 in not only a prognostic biomarker, but also may play a key role in controlling tumor immune microenvironment in gliomas. These findings suggest that C5AR2 is a potential prognostic marker and immunotherapeutic target in glioma.

- [Abstract](/doi/abs/10.1002/cai2.29 "Abstract")
- [Full text](/doi/full/10.1002/cai2.29 "Full text")
- [PDF](/doi/epdf/10.1002/cai2.29 "EPDF")
- [References](/doi/full/10.1002/cai2.29#reference "References")
- [Request permissions](https://onlinelibrary.wiley.com/action/rightsLink?doi=10.1002%2Fcai2.29&mode= "Request permissions")

ORIGINAL ARTICLE

Open access

[**Identification of prognostic indicators, diagnostic markers, and possible therapeutic targets among LIM homeobox transcription factors in breast cancer**](/doi/10.1002/cai2.30 "Identification of prognostic indicators, diagnostic markers, and possible therapeutic targets among LIM homeobox transcription factors in breast cancer")

[Pingping Gao](/authored-by/Gao/Pingping), [Na Sun](/authored-by/Sun/Na), [Tingting Zhao](/authored-by/Zhao/Tingting), [Yuanyuan Sun](/authored-by/Sun/Yuanyuan), [Jing Gu](/authored-by/Gu/Jing), [Dandan Ma](/authored-by/Ma/Dandan), [Hao Tian](/authored-by/Tian/Hao), [Zaihui Peng](/authored-by/Peng/Zaihui), [Yi Zhang](/authored-by/Zhang/Yi), [Fei Han](/authored-by/Han/Fei), [Xiaowei Qi](/authored-by/Qi/Xiaowei),

- [Cancer Innovation](/journal/27709183)
- Pages: 252-269
- First Published:  26 September 2022

### Graphical Abstract

[![Identification of prognostic indicators, diagnostic markers, and possible therapeutic targets among LIM homeobox transcription factors in breast cancer Issue 3, 2022](/cms/asset/4b51332b-672e-421e-a92e-ca5f42509b96/cai230-gra-0001-m.jpg)](/cms/asset/4b51332b-672e-421e-a92e-ca5f42509b96/cai230-gra-0001-m.jpg "Link to full-size graphical abstract")

LHXs are potential and unique diagnostic and prognostic markers in BRCA, and possibly participate in the development and progression of BRCA in different manners through various signaling pathways and/or regulatory mechanisms.

- [Abstract](/doi/abs/10.1002/cai2.30 "Abstract")
- [Full text](/doi/full/10.1002/cai2.30 "Full text")
- [PDF](/doi/epdf/10.1002/cai2.30 "EPDF")
- [References](/doi/full/10.1002/cai2.30#reference "References")
- [Request permissions](https://onlinelibrary.wiley.com/action/rightsLink?doi=10.1002%2Fcai2.30&mode= "Request permissions")

ORIGINAL ARTICLE

Open access

[**Prognostic value of lactate transporter SLC16A1 and SLC16A3 as oncoimmunological biomarkers associating tumor metabolism and immune evasion in glioma**](/doi/10.1002/cai2.32 "Prognostic value of lactate transporter SLC16A1 and SLC16A3 as oncoimmunological biomarkers associating tumor metabolism and immune evasion in glioma")

[Ting Zhu](/authored-by/Zhu/Ting), [Xiaoqin Ge](/authored-by/Ge/Xiaoqin), [Shengping Gong](/authored-by/Gong/Shengping), [Shenchao Guo](/authored-by/Guo/Shenchao), [Qingsong Tao](/authored-by/Tao/Qingsong), [Jianxin Guo](/authored-by/Guo/Jianxin), [Ruishuang Ma](/authored-by/Ma/Ruishuang),

- [Cancer Innovation](/journal/27709183)
- Pages: 229-239
- First Published:  12 October 2022

### Graphical Abstract

[![Prognostic value of lactate transporter SLC16A1 and SLC16A3 as oncoimmunological biomarkers associating tumor metabolism and immune evasion in glioma Issue 3, 2022](/cms/asset/e626df3c-130a-44e9-a01d-890898ea3b69/cai232-gra-0001-m.jpg)](/cms/asset/e626df3c-130a-44e9-a01d-890898ea3b69/cai232-gra-0001-m.jpg "Link to full-size graphical abstract")

Both SLC16A1 and SLC16A3 expression were increased in LGG and GBM. GO analysis indicated that SLC16A1 was related to Herpes simplex virus 1 infection while SLC16A3 was involved in neutrophil activation. SLC16A3 as well as SLC16A1 were closely related to immune infiltration and checkpoints LGG and GBM.

- [Abstract](/doi/abs/10.1002/cai2.32 "Abstract")
- [Full text](/doi/full/10.1002/cai2.32 "Full text")
- [PDF](/doi/epdf/10.1002/cai2.32 "EPDF")
- [References](/doi/full/10.1002/cai2.32#reference "References")
- [Request permissions](https://onlinelibrary.wiley.com/action/rightsLink?doi=10.1002%2Fcai2.32&mode= "Request permissions")

[More articles](/action/doSearch?SeriesKey=27709183&sortBy=cited "More articles")

The most read articles published in the Last 2 Years

REVIEW

Open access

[**Organoid co‐culture models of the tumor microenvironment promote precision medicine**](/doi/10.1002/cai2.101 "Organoid co‐culture models of the tumor microenvironment promote precision medicine")

[Zhaoru Gu](/authored-by/Gu/Zhaoru), [Quanyou Wu](/authored-by/Wu/Quanyou), [Bingqing Shang](/authored-by/Shang/Bingqing), [Kaitai Zhang](/authored-by/Zhang/Kaitai), [Wen Zhang](/authored-by/Zhang/Wen),

- [Cancer Innovation](/journal/27709183)
- First Published:  17 December 2023

### Graphical Abstract

[![Organoid co-culture models of the tumor microenvironment promote precision medicine Issue 1, 2024](/cms/asset/3e528de6-6f3a-4ecb-a864-6f81f9b5c2f8/cai2101-gra-0001-m.jpg)](/cms/asset/3e528de6-6f3a-4ecb-a864-6f81f9b5c2f8/cai2101-gra-0001-m.jpg "Link to full-size graphical abstract")

Three dimensional (3D) culture is a promising model for tumor research, replicating solid tumor characteristics. Advantages include high throughput and retention of heterogeneity. Traditional matrigel-submerged organoid culture requires exogenous cells to study the tumor microenvironment (TME). A holistic approach using patient-derived tumor fragments (PDTFs), air-liquid interface (ALI), suspension 3D culture, and microfluidic tumor-on-chip (ToC) models better mimic the tumor structure and composition. Organoid co-culture models are useful for studying the TME, immunotherapy, biomarkers, drug screening, and infections. These 3D systems aim to improve therapeutic approaches and patient outcomes.

- [Abstract](/doi/abs/10.1002/cai2.101 "Abstract")
- [Full text](/doi/full/10.1002/cai2.101 "Full text")
- [PDF](/doi/epdf/10.1002/cai2.101 "EPDF")
- [References](/doi/full/10.1002/cai2.101#reference "References")
- [Request permissions](https://onlinelibrary.wiley.com/action/rightsLink?doi=10.1002%2Fcai2.101&mode= "Request permissions")

REVIEW

Open access

[**Advances in medical treatment of breast cancer in 2022**](/doi/10.1002/cai2.46 "Advances in medical treatment of breast cancer in 2022")

[Jingtong Zhai](/authored-by/Zhai/Jingtong), [Yun Wu](/authored-by/Wu/Yun), [Fei Ma](/authored-by/Ma/Fei), [Virginia Kaklamani](/authored-by/Kaklamani/Virginia), [Binghe Xu](/authored-by/Xu/Binghe),

- [Cancer Innovation](/journal/27709183)
- Pages: 1-17
- First Published:  21 February 2023

### Graphical Abstract

[![Advances in medical treatment of breast cancer in 2022 Issue 1, 2023](/cms/asset/9d9de681-3ae7-4715-b91b-6e6d795e6ac8/cai246-gra-0001-m.jpg)](/cms/asset/9d9de681-3ae7-4715-b91b-6e6d795e6ac8/cai246-gra-0001-m.jpg "Link to full-size graphical abstract")

This article summarizes the annual progress of breast cancer chemotherapy, targeted therapy, endocrine therapy and immunotherapy in 2022, providing valuable information for future research to better guide individualized treatment of breast cancer, thereby improving the prognosis and quality of life of breast cancer patients.

- [Abstract](/doi/abs/10.1002/cai2.46 "Abstract")
- [Full text](/doi/full/10.1002/cai2.46 "Full text")
- [PDF](/doi/epdf/10.1002/cai2.46 "EPDF")
- [References](/doi/full/10.1002/cai2.46#reference "References")
- [Request permissions](https://onlinelibrary.wiley.com/action/rightsLink?doi=10.1002%2Fcai2.46&mode= "Request permissions")

REVIEW

Open access

[**Global trends of cancer: The role of diet, lifestyle, and environmental factors**](/doi/10.1002/cai2.76 "Global trends of cancer: The role of diet, lifestyle, and environmental factors")

[Hassan Bahrami](/authored-by/Bahrami/Hassan), [Majid Tafrihi](/authored-by/Tafrihi/Majid),

- [Cancer Innovation](/journal/27709183)
- Pages: 290-301
- First Published:  25 July 2023

### Graphical Abstract

[![Global trends of cancer: The role of diet, lifestyle, and environmental factors Issue 4, 2023](/cms/asset/30ccb41d-fdfe-4080-9fd3-53d12666ef05/cai276-gra-0001-m.jpg)](/cms/asset/30ccb41d-fdfe-4080-9fd3-53d12666ef05/cai276-gra-0001-m.jpg "Link to full-size graphical abstract")

The age-standardized cancer incidence rate data for the selected countries indicate a great areal variation and different global trends for each type of cancer. Analysis of the worldwide statistical data regionally for cancer incidence rates for certain cancers meaningfully correlate with diet, lifestyle, and environmental factors.

- [Abstract](/doi/abs/10.1002/cai2.76 "Abstract")
- [Full text](/doi/full/10.1002/cai2.76 "Full text")
- [PDF](/doi/epdf/10.1002/cai2.76 "EPDF")
- [References](/doi/full/10.1002/cai2.76#reference "References")
- [Request permissions](https://onlinelibrary.wiley.com/action/rightsLink?doi=10.1002%2Fcai2.76&mode= "Request permissions")

REVIEW

Open access

[**Progress in phase III clinical trials of molecular targeted therapy and immunotherapy for glioblastoma**](/doi/10.1002/cai2.59 "Progress in phase III clinical trials of molecular targeted therapy and immunotherapy for glioblastoma")

[Yuekun Wang](/authored-by/Wang/Yuekun), [Shenglan Li](/authored-by/Li/Shenglan), [Yichen Peng](/authored-by/Peng/Yichen), [Wenbin Ma](/authored-by/Ma/Wenbin), [Yu Wang](/authored-by/Wang/Yu), [Wenbin Li](/authored-by/Li/Wenbin),

- [Cancer Innovation](/journal/27709183)
- Pages: 114-130
- First Published:  5 March 2023

### Graphical Abstract

[![Progress in phase III clinical trials of molecular targeted therapy and immunotherapy for glioblastoma Issue 2, 2023](/cms/asset/eab047ee-cb1f-4635-8a19-6db6b97c8646/cai259-gra-0001-m.jpg)](/cms/asset/eab047ee-cb1f-4635-8a19-6db6b97c8646/cai259-gra-0001-m.jpg "Link to full-size graphical abstract")

A wide variety of targeted drugs and immunotherapies are tested for patients with glioblastoma, but not all of these drugs are effective, and only a few of these trials have prolonged the lives of patients. We summarize the phase III clinical trial of target therapy and inmmunotherapy for glioblastoma and discuss the challenge faced contemporaneously and prospects of targeted drugs and immunotherapy in the future.

- [Abstract](/doi/abs/10.1002/cai2.59 "Abstract")
- [Full text](/doi/full/10.1002/cai2.59 "Full text")
- [PDF](/doi/epdf/10.1002/cai2.59 "EPDF")
- [References](/doi/full/10.1002/cai2.59#reference "References")
- [Request permissions](https://onlinelibrary.wiley.com/action/rightsLink?doi=10.1002%2Fcai2.59&mode= "Request permissions")

REVIEW

Open access

[**Recent advances in immunotherapy for lung cancer**](/doi/10.1002/cai2.55 "Recent advances in immunotherapy for lung cancer")

[Qi Wang](/authored-by/Wang/Qi), [Chunxia Su](/authored-by/Su/Chunxia), [Caicun Zhou](/authored-by/Zhou/Caicun),

- [Cancer Innovation](/journal/27709183)
- Pages: 18-24
- First Published:  24 February 2023

### Graphical Abstract

[![Recent advances in immunotherapy for lung cancer Issue 1, 2023](/cms/asset/d976bba2-192c-4e23-acc1-824ea2956cf3/cai255-gra-0001-m.jpg)](/cms/asset/d976bba2-192c-4e23-acc1-824ea2956cf3/cai255-gra-0001-m.jpg "Link to full-size graphical abstract")

In recent years, immunotherapy has gradually moved from the back line to the front line, from advanced to early patients. This article focuses on the latest developments in perioperative and advanced lung cancer immunotherapy, discusses the problems and challenges at the current stage, and explores new directions for future development.

- [Abstract](/doi/abs/10.1002/cai2.55 "Abstract")
- [Full text](/doi/full/10.1002/cai2.55 "Full text")
- [PDF](/doi/epdf/10.1002/cai2.55 "EPDF")
- [References](/doi/full/10.1002/cai2.55#reference "References")
- [Request permissions](https://onlinelibrary.wiley.com/action/rightsLink?doi=10.1002%2Fcai2.55&mode= "Request permissions")

REVIEW

Open access

[**A comprehensive review of 3D cancer models for drug screening and translational research**](/doi/10.1002/cai2.102 "A comprehensive review of 3D cancer models for drug screening and translational research")

[Karthikey Sharma](/authored-by/Sharma/Karthikey), [Sreenath Dey](/authored-by/Dey/Sreenath), [Rounik Karmakar](/authored-by/Karmakar/Rounik), [Aravind Kumar Rengan](/authored-by/Rengan/Aravind+Kumar),

- [Cancer Innovation](/journal/27709183)
- First Published:  22 December 2023

### Graphical Abstract

[![A comprehensive review of 3D cancer models for drug screening and translational research Issue 1, 2024](/cms/asset/c9eec54e-1653-4b54-8991-c85efda880ad/cai2102-gra-0001-m.jpg)](/cms/asset/c9eec54e-1653-4b54-8991-c85efda880ad/cai2102-gra-0001-m.jpg "Link to full-size graphical abstract")

This review discusses the vast valuable importance of Tumor microenvironment (TME) recapitulation in cancer research prioritizing individual roles of TME elements in the histopathology of cancer. Further, the review broadly describes of few of the recently developed 3D models that have their main focus restricted to drug development and their screening and/or implications of the approach in preclinical as well as translational research.

- [Abstract](/doi/abs/10.1002/cai2.102 "Abstract")
- [Full text](/doi/full/10.1002/cai2.102 "Full text")
- [PDF](/doi/epdf/10.1002/cai2.102 "EPDF")
- [References](/doi/full/10.1002/cai2.102#reference "References")
- [Request permissions](https://onlinelibrary.wiley.com/action/rightsLink?doi=10.1002%2Fcai2.102&mode= "Request permissions")

CLINICAL GUIDELINE

Open access

[**Clinical practice guidelines for full‐cycle standardized management of bone health in breast cancer patients**](/doi/10.1002/cai2.111 "Clinical practice guidelines for full‐cycle standardized management of bone health in breast cancer patients")

[Committee of Full-cycle Standardized Management of Bone Health in Breast Cancer Patients](/authored-by/ContribRaw/Committee+of+Full%E2%80%90cycle+Standardized+Management+of+Bone+Health+in+Breast+Cancer+Patients),

- [Cancer Innovation](/journal/27709183)
- First Published:  29 February 2024

### Graphical Abstract

[![Clinical practice guidelines for full-cycle standardized management of bone health in breast cancer patients Issue 1, 2024](/cms/asset/7f23194d-8d35-4190-ab5f-06a823a8063a/cai2111-gra-0001-m.jpg)](/cms/asset/7f23194d-8d35-4190-ab5f-06a823a8063a/cai2111-gra-0001-m.jpg "Link to full-size graphical abstract")

This guideline has been developed by the Breast Cancer Expert Committee of the National Cancer Quality Control Center. The experts involved in this guideline have thoroughly examined the comprehensive management of bone health in breast cancer, aiming to establish a reference framework for managing bone health and standardizing the diagnosis and treatment of breast cancer patients.

- [Abstract](/doi/abs/10.1002/cai2.111 "Abstract")
- [Full text](/doi/full/10.1002/cai2.111 "Full text")
- [PDF](/doi/epdf/10.1002/cai2.111 "EPDF")
- [References](/doi/full/10.1002/cai2.111#reference "References")
- [Request permissions](https://onlinelibrary.wiley.com/action/rightsLink?doi=10.1002%2Fcai2.111&mode= "Request permissions")

REVIEW

Open access

[**Applications of digital Medicine in oncology: Prospects and challenges**](/doi/10.1002/cai2.37 "Applications of digital Medicine in oncology: Prospects and challenges")

[Hewei Ge](/authored-by/Ge/Hewei), [Lixi Li](/authored-by/Li/Lixi), [Di Zhang](/authored-by/Zhang/Di), [Fei Ma](/authored-by/Ma/Fei),

- [Cancer Innovation](/journal/27709183)
- Pages: 285-292
- First Published:  4 December 2022

### Graphical Abstract

[![Applications of digital Medicine in oncology: Prospects and challenges Issue 4, 2022](/cms/asset/544b0446-0534-4881-a9ab-6cf55182942b/cai237-gra-0001-m.jpg)](/cms/asset/544b0446-0534-4881-a9ab-6cf55182942b/cai237-gra-0001-m.jpg "Link to full-size graphical abstract")

This review summarizes the applications of digital medicine in cancer prevention, screening, diagnosis, and treatment, as well as clinical trials. Integrating digital medicine into clinical practice has the advantages of broader applicability, greater cost-effectiveness, better accessibility, and improved diagnostic and therapeutic performance.

- [Abstract](/doi/abs/10.1002/cai2.37 "Abstract")
- [Full text](/doi/full/10.1002/cai2.37 "Full text")
- [PDF](/doi/epdf/10.1002/cai2.37 "EPDF")
- [References](/doi/full/10.1002/cai2.37#reference "References")
- [Request permissions](https://onlinelibrary.wiley.com/action/rightsLink?doi=10.1002%2Fcai2.37&mode= "Request permissions")

ORIGINAL ARTICLE

Open access

[**Prediction of death rates for cardiovascular diseases and cancers**](/doi/10.1002/cai2.47 "Prediction of death rates for cardiovascular diseases and cancers")

[Oleg Gaidai](/authored-by/Gaidai/Oleg), [Yihan Xing](/authored-by/Xing/Yihan), [Rajiv Balakrishna](/authored-by/Balakrishna/Rajiv), [Jiayao Sun](/authored-by/Sun/Jiayao), [Xiaolong Bai](/authored-by/Bai/Xiaolong),

- [Cancer Innovation](/journal/27709183)
- Pages: 140-147
- First Published:  9 February 2023

### Graphical Abstract

[![Prediction of death rates for cardiovascular diseases and cancers Issue 2, 2023](/cms/asset/e1696cca-f868-4c47-835e-0f06ce6579ec/cai247-gra-0001-m.jpg)](/cms/asset/e1696cca-f868-4c47-835e-0f06ce6579ec/cai247-gra-0001-m.jpg "Link to full-size graphical abstract")

A novel health system reliability method has been developed and applied to cardio and cancer death rate data. Accurate disease multiregional prediction is done.

- [Abstract](/doi/abs/10.1002/cai2.47 "Abstract")
- [Full text](/doi/full/10.1002/cai2.47 "Full text")
- [PDF](/doi/epdf/10.1002/cai2.47 "EPDF")
- [References](/doi/full/10.1002/cai2.47#reference "References")
- [Request permissions](https://onlinelibrary.wiley.com/action/rightsLink?doi=10.1002%2Fcai2.47&mode= "Request permissions")

REVIEW

Open access

[**Radiotherapy, photodynamic therapy, and cryoablation‐induced abscopal effect: Challenges and future prospects**](/doi/10.1002/cai2.53 "Radiotherapy, photodynamic therapy, and cryoablation‐induced abscopal effect: Challenges and future prospects")

[Sadik Ali Mohammad](/authored-by/Ali+Mohammad/Sadik), [Arshadul Hak](/authored-by/Hak/Arshadul), [Sunil V. Pogu](/authored-by/Pogu/Sunil+V.), [Aravind K. Rengan](/authored-by/Rengan/Aravind+K.),

- [Cancer Innovation](/journal/27709183)
- Pages: 323-345
- First Published:  23 February 2023

### Graphical Abstract

[![Radiotherapy, photodynamic therapy, and cryoablation-induced abscopal effect: Challenges and future prospects Issue 5, 2023](/cms/asset/1e8aa043-569e-46fe-bacf-be2f103bd8f2/cai253-gra-0001-m.jpg)](/cms/asset/1e8aa043-569e-46fe-bacf-be2f103bd8f2/cai253-gra-0001-m.jpg "Link to full-size graphical abstract")

- Primary or local tumor ablation following local therapy (such as radiotherapy, photodynamic therapy, and cryoablation) causes the release of damage-associated molecular proteins and tumor-associated antigens, which are then presented to dendritic cells (antigen-presenting cells) and results in the development of a systemic antitumor immune response, or “abscopal effect.”


- However, the immune-suppressive tumor microenvironment blocks the antitumor immune response through several mechanisms, including the immune checkpoint mechanism (programmed death-1, programmed death ligand-1, and cytotoxic T lymphocyte-associated protein-4) and the overexpression of immunosuppressive cells myeloid-derived T-regulatory cells, myeloid-derived suppressor cells, and tumor-associated macrophages, and so on.


- The use of immunotherapy can be used to treat these immune suppression mechanisms. Therefore, local therapy and immunotherapy combined have been proven to provide an effective abscopal impact. Immune-related adverse effects, however, can result from immunotherapy. Determining the precise sort of immunosuppressive mechanism and using specialized immunotherapy can combat these drawbacks. This can be achieved by using a nanotheranostic method, in which nanoparticles are loaded with prognostic biomarkers and predictive biomarkers, and to develop a strategy that could be multifaceted and address all potential obstacles that slow the abscopal impact.


- [Abstract](/doi/abs/10.1002/cai2.53 "Abstract")
- [Full text](/doi/full/10.1002/cai2.53 "Full text")
- [PDF](/doi/epdf/10.1002/cai2.53 "EPDF")
- [References](/doi/full/10.1002/cai2.53#reference "References")
- [Request permissions](https://onlinelibrary.wiley.com/action/rightsLink?doi=10.1002%2Fcai2.53&mode= "Request permissions")

[More articles](/action/doSearch?SeriesKey=27709183&sortBy=read "More articles")

## Latest news

[More news >](/allnews/27709183 "More news")

## Recent issues

- [![Cancer Innovation](/cms/asset/6b6b75da-29c3-4cb7-a0a3-c17a0026dbd2/cai2.v3.5.cover.gif)](/toc/27709183/2024/3/5 "Cancer Innovation")

[Volume 3, Issue 5](/toc/27709183/2024/3/5 "View Table of Contents for Cancer Innovation volume 3 issue 5")

October 2024

- [![Cancer Innovation](/cms/asset/52f17d74-1d0f-4bd6-9beb-0b9b03bfead3/cai2.v3.4.cover.gif)](/toc/27709183/2024/3/4 "Cancer Innovation")

[Volume 3, Issue 4](/toc/27709183/2024/3/4 "View Table of Contents for Cancer Innovation volume 3 issue 4")

August 2024

- [![Cancer Innovation](/cms/asset/c85d274c-b5e5-4df0-a775-0571f1c0027a/cai2.v3.3.cover.gif)](/toc/27709183/2024/3/3 "Cancer Innovation")

[Volume 3, Issue 3](/toc/27709183/2024/3/3 "View Table of Contents for Cancer Innovation volume 3 issue 3")

June 2024

- [![Cancer Innovation](/cms/asset/0ddcc2b1-4ee4-49e9-9bef-2e13bf4378b7/cai2.v3.2.cover.gif)](/toc/27709183/2024/3/2 "Cancer Innovation")

[Volume 3, Issue 2](/toc/27709183/2024/3/2 "View Table of Contents for Cancer Innovation volume 3 issue 2")

April 2024


### Sign up for email alerts

Enter your email to receive alerts when new articles and issues are published.

Email address\*

Please select your location and accept the terms of use.

Country or location\*

Open this select menuAfghanistanÅland IslandsAlbaniaAlgeriaAmerican SamoaAndorraAngolaAnguillaAntarcticaAntigua And BarbudaArgentinaArmeniaArubaAustraliaAustriaAzerbaijanBahamasBahrainBangladeshBarbadosBelarusBelgiumBelizeBeninBermudaBhutanBoliviaBonaire, Sint Eustatius And SabaBosnia And HerzegovinaBotswanaBouvet IslandBrazilBritish Indian Ocean TerritoryBrunei DarussalamBulgariaBurkina FasoBurundiCambodiaCameroonCanadaCape VerdeCayman IslandsCentral African RepublicChadChileChinaChristmas IslandCocos (keeling) IslandsColombiaComorosCongoCongo, The Democratic Republic Of TheCook IslandsCosta RicaCôte D'ivoireCroatiaCubaCuraçaoCyprusCzech RepublicDenmarkDjiboutiDominicaDominican RepublicEcuadorEgyptEl SalvadorEquatorial GuineaEritreaEstoniaEthiopiaFalkland Islands (malvinas)Faroe IslandsFijiFinlandFranceFrench GuianaFrench PolynesiaFrench Southern TerritoriesGabonGambiaGeorgiaGermanyGhanaGibraltarGreeceGreenlandGrenadaGuadeloupeGuamGuatemalaGuernseyGuineaGuinea-bissauGuyanaHaitiHeard Island And Mcdonald IslandsHoly See (vatican City State)HondurasHong KongHungaryIcelandIndiaIndonesiaIran, Islamic Republic OfIraqIrelandIsle Of ManIsraelItalyJamaicaJapanJerseyJordanKazakhstanKenyaKiribatiKorea, Democratic People's Republic OfKorea, Republic OfKosovo, Republic OfKuwaitKyrgyzstanLao People's Democratic RepublicLatviaLebanonLesothoLiberiaLibyan Arab JamahiriyaLiechtensteinLithuaniaLuxembourgMacaoMacedonia, The Former Yugoslav Republic OfMadagascarMalawiMalaysiaMaldivesMaliMaltaMarshall IslandsMartiniqueMauritaniaMauritiusMayotteMexicoMicronesia, Federated States OfMoldova, Republic OfMonacoMongoliaMontenegroMontserratMoroccoMozambiqueMyanmarNamibiaNauruNepalNetherlandsNetherlands AntillesNew CaledoniaNew ZealandNicaraguaNigerNigeriaNiueNorfolk IslandNorthern Mariana IslandsNorwayOmanPakistanPalauPalestinian Territory, OccupiedPanamaPapua New GuineaParaguayPeruPhilippinesPitcairnPolandPortugalPuerto RicoQatarReunionRomaniaRussian FederationRwandaSaint BarthélemySaint HelenaSaint Kitts And NevisSaint LuciaSaint MartinSaint Pierre And MiquelonSaint Vincent And The GrenadinesSamoaSan MarinoSao Tome And PrincipeSaudi ArabiaSenegalSerbiaSeychellesSierra LeoneSingaporeSint MaartenSlovakiaSloveniaSolomon IslandsSomaliaSouth AfricaSouth Georgia And The South Sandwich IslandsSouth SudanSpainSri LankaSudanSurinameSvalbard And Jan MayenSwazilandSwedenSwitzerlandSyrian Arab RepublicTaiwanTajikistanTanzania, United Republic OfThailandTimor-lesteTogoTokelauTongaTrinidad And TobagoTunisiaTürkiyeTurkmenistanTurks And Caicos IslandsTuvaluUgandaUkraineUnited Arab EmiratesUnited KingdomUnited StatesUnited States Minor Outlying IslandsUruguayUzbekistanVanuatuVenezuela, Bolivarian Republic OfViet NamVirgin Islands, BritishVirgin Islands, U.s.Wallis And FutunaWestern SaharaYemenZambiaZimbabwe

I consent to Wiley Online Library’s
[Terms of Use](https://onlinelibrary.wiley.com/termsAndConditions) and processing of my personal data as disclosed in Wiley’s [Privacy Policy](https://www.wiley.com/privacy). _\*_I consent to my personal information being transferred outside of the People’s Republic of China as laid out in Wiley’s Privacy Policy.\*(Optional) I consent to special offers,

newsletter & promotions from Wiley.
See [Privacy Policy](https://www.wiley.com/privacy) for more details.

Sign up to alerts

Continue

- [Journal Metrics](/journal/27709183/journal-metrics)

## Tools

- [Submit an article](https://mc.manuscriptcentral.com/cancerinnovation)

### Peer-Review Metrics

- Submission to first decision: **32**
- Submission to final decision: **58**
- Submission to acceptance: **65**

\\* Median number of days in 2023

An official journal of Boao Cancer Innovation Institue, published on behalf of [Tsinghua University Press](http://www.tup.tsinghua.edu.cn/en/index.html/).

![](/pb-assets/assets/27709183/BCI-logo-1641369351.png)

[![](/pb-assets/assets/27709183/Tsinghua new logo-1669044070.png)](http://www.tup.tsinghua.edu.cn/en/index.html/)

## More from this journal

- [Celebrating the First Anniversary](/page/journal/27709183/homepage/firstanniversary)
- [Call for Papers](/page/journal/27709183/homepage/callforpapers)
- [Author Guidelines](/page/journal/27709183/homepage/author-guidelines)
- [Publish Open Access at No Cost](/page/journal/27709183/homepage/open-access)
- [Get Help Getting Published](/page/journal/27711757/homepage/author-guidelines)
- [Learn More About Open Access](https://www.wiley.com/network/researchers/open-access-week-2020-open-with-purpose/10-things-you-need-to-know-about-wiley-open-access-2)
- [Promote Your Work](https://authorservices.wiley.com/author-resources/Journal-Authors/Promotion/index.html)
- [Editor's Highlights](/page/journal/27709183/homepage/editors_highlights)

[![](/pb-assets/assets/27709183/CAI2_TC_Glioblastoma_300x250-1690786644.png)](/doi/toc/10.1002/(ISSN)2770-9183.glioblastoma)

##### Understanding Open Access

As an open access journal, all articles in _Cancer Innovation_ are freely available to read, download and share immediately on publication. Learn more about open access:

* * *

## More TUP journals

- [![Health Care Science](/cms/asset/acec1809-d1c9-479a-a2aa-3ee0eb01de4c/hcs2.v3.4.cover.gif)](/journal/27711757 "Health Care Science")

Issue [Volume 3, Issue 4](/journal/27711757 "View the homepage for Health Care Science")

August 2024

- [![THEMED SECTION: Clinical application and novels of ultra‐high field MRI cover image](/cms/asset/bafb4f8c-95c4-415b-99b5-d86d7d690d2a/ird3.v2.4.cover.gif)](/journal/28342879 "THEMED SECTION: Clinical application and novels of ultra‐high field MRI cover image")

Issue [Volume 2, Issue 4](/journal/28342879 "View the homepage for iRADIOLOGY") [**THEMED SECTION: Clinical application and novels of ultra‐high field MRI**](/toc/28342879/2024/2/4)

August 2024



Issue Edited by:


Bo Gao, Danny JJ Wang

- [![iLABMED](/cms/asset/1802d1cb-621b-4722-b916-48122de0f899/ila2.v2.2.cover.gif)](/journal/28344448 "iLABMED")

Issue [Volume 2, Issue 2](/journal/28344448 "View the homepage for iLABMED")

June 2024

- [![Medicine Advances](/cms/asset/4f548d75-ab8e-44e3-a2fc-64a2c928b406/med4.v2.2.cover.gif)](/journal/28344405 "Medicine Advances")

Issue [Volume 2, Issue 2](/journal/28344405 "View the homepage for Medicine Advances")

June 2024


## Relevant OA journals

- [![Aging and Cancer](/cms/asset/0dbaab6a-42a8-4dcc-bf2d-4c2de6a8accb/aac2.v5.1-2.cover.gif)](/journal/26438909 "Aging and Cancer")

Issue [Volume 5, Issue 1-2](/journal/26438909 "View the homepage for Aging and Cancer")

June 2024

- [![Cancer Communications](/cms/asset/88c3c2ca-93dd-4e67-909c-3018572a502d/cac2.v44.8.cover.gif)](/journal/25233548 "Cancer Communications")

Issue [Volume 44, Issue 8](/journal/25233548 "View the homepage for Cancer Communications")

August 2024

- [![Cancer Medicine](/cms/asset/f999ef10-211f-4620-88a2-07f00c87d674/cam4.v13.17.cover.gif)](/journal/20457634 "Cancer Medicine")

Issue [Volume 13, Issue 17](/journal/20457634 "View the homepage for Cancer Medicine")

September 2024

- [![Cancer Reports](/cms/asset/fcdf1128-ba27-4256-9734-cb2b70e67f53/cnr2.v7.9.cover.gif)](/journal/25738348 "Cancer Reports")

Issue [Volume 7, Issue 9](/journal/25738348 "View the homepage for Cancer Reports")

September 2024

- [![Clinical and Translational Medicine](/cms/asset/d7925222-6a09-48c8-9848-9d2cfb29681d/ctm2.v14.9.cover.gif)](/journal/20011326 "Clinical and Translational Medicine")

Issue [Volume 14, Issue 9](/journal/20011326 "View the homepage for Clinical and Translational Medicine")

September 2024

- [![MedComm](/cms/asset/6802e721-dee3-4ea8-9d59-cd9ada28aa19/mco2.v5.9.cover.gif)](/journal/26882663 "MedComm")

Issue [Volume 5, Issue 9](/journal/26882663 "View the homepage for MedComm")

September 2024

- [![MedComm &#8211; Oncology](/cms/asset/efd7c56f-3400-489a-9af7-029579621f7d/mog2.v3.3.cover.gif)](/journal/27696448 "MedComm &#8211; Oncology")

Issue [Volume 3, Issue 3](/journal/27696448 "View the homepage for MedComm &#8211; Oncology")

September 2024

- [![Precision Medical Sciences](/cms/asset/72933ad1-ede5-4985-9bfc-5531ffab200d/prm2.v13.2.cover.gif)](/journal/26422514 "Precision Medical Sciences")

Issue [Volume 13, Issue 2](/journal/26422514 "View the homepage for Precision Medical Sciences")

June 2024

- [![Thoracic Cancer](/cms/asset/69b98a93-80bd-419e-b806-7e8a300b4b6b/tca.v15.25.cover.gif)](/journal/17597714 "Thoracic Cancer")

Issue [Volume 15, Issue 25](/journal/17597714 "View the homepage for Thoracic Cancer")

September 2024


# Journal list menu

- Journal

- _![](/pb-assets/hub-assets/pericles/articles_1-1499257321163.png)_ Articles


- Actions


## Tools







## Follow journal


## Additional links

### About Wiley Online Library

- [Privacy Policy](https://www.wiley.com/privacy)
- [Terms of Use](https://onlinelibrary.wiley.com/terms-and-conditions)
- [About Cookies](https://onlinelibrary.wiley.com/cookies)
- Manage Cookies
- [Accessibility](https://onlinelibrary.wiley.com/accessibility)
- [Wiley Research DE&I Statement and Publishing Policies](https://onlinelibrary.wiley.com/publishing-policies)
- [Developing World Access](https://onlinelibrary.wiley.com/developing-world-access)

### Help & Support

- [Contact Us](https://hub.wiley.com/community/support/onlinelibrary)
- [Training and Support](https://www.wiley.com/customer-success/wiley-online-library-training-hub)
- [DMCA & Reporting Piracy](https://onlinelibrary.wiley.com/dmca-notification-policy)

### Opportunities

- [Subscription Agents](https://onlinelibrary.wiley.com/agents)
- [Advertisers & Corporate Partners](https://onlinelibrary.wiley.com/advertisers)

### Connect with Wiley

- [The Wiley Network](https://www.wiley.com/network)
- [Wiley Press Room](https://newsroom.wiley.com/)

Copyright © 1999-2024 [John Wiley & Sons, Inc](https://www.wiley.com) or related companies. All rights reserved, including rights for text and data mining and training of artificial intelligence technologies or similar technologies.

[![Wiley Home Page](/pb-assets/tmp-images/footer-logo-wiley-1510029248417.png)](https://www.wiley.com "Wiley Home Page")

![](/pb-assets/hub-assets/pericles/logo-header-1690978619437.png)

## Log in to Wiley Online Library

Email or Customer ID

Password

[Forgot password?](/action/requestResetPassword)

[NEW USER >](/action/registration?acdl-redirect=true) [INSTITUTIONAL LOGIN >](/action/ssostart?redirectUri=%2Fjournal%2F27709183)

![](/pb-assets/hub-assets/pericles/logo-header-1690978619437.png)

## Change Password

Old Password

New Password

Too ShortWeakMediumStrongVery StrongToo Long

#### Your password must have 10 characters or more:

- a lower case character,
- an upper case character,
- a special character
- or a digit

Too Short

## Password Changed Successfully

Your password has been changed

## Create a new account

Email

[Returning user](/action/showLogin)

![](/pb-assets/hub-assets/pericles/logo-header-1690978619437.png)

## Forgot your password?

Enter your email address below.

Email

Please check your email for instructions on resetting your password.
If you do not receive an email within 10 minutes, your email address may not be registered,
and you may need to create a new Wiley Online Library account.

## Request Username

Can't sign in? Forgot your username?

Enter your email address below and we will send you your username

Email

Close

If the address matches an existing account you will receive an email with instructions to retrieve your username